Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
69.09
+2.48 (3.72%)
Feb 23, 2026, 12:50 PM EST - Market open

Tarsus Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Feb '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
2,9332,117670391465840
Market Cap Growth
34.74%215.74%71.44%-15.95%-44.60%-
Enterprise Value
2,5471,873455185283857
Last Close Price
66.6155.3720.2514.6622.5041.33
PS Ratio
7.8311.5738.4215.158.16-
PB Ratio
8.449.433.402.032.795.06
P/TBV Ratio
8.759.793.472.032.795.06
P/FCF Ratio
----147.13-
P/OCF Ratio
----124.13-
EV/Sales Ratio
6.9610.2426.107.154.96-
EV/FCF Ratio
----89.41-
Debt / Equity Ratio
0.250.320.150.100.010.01
Debt / FCF Ratio
----0.38-
Net Debt / Equity Ratio
-0.95-0.97-1.00-1.02-1.02-1.01
Net Debt / EBITDA Ratio
3.731.831.393.1614.406.22
Net Debt / FCF Ratio
5.552.591.663.97-53.967.75
Asset Turnover
0.800.570.070.130.33-
Inventory Turnover
26.2923.12----
Quick Ratio
4.074.216.6414.3014.9831.21
Current Ratio
4.294.436.9314.6115.3331.68
Return on Equity (ROE)
-28.35%-54.83%-69.71%-34.53%-8.31%-24.01%
Return on Assets (ROA)
-12.00%-23.46%-36.27%-19.27%-4.33%-14.65%
Return on Capital Employed (ROCE)
-20.90%-40.70%-62.60%-29.50%-7.30%-16.20%
Earnings Yield
-2.83%-5.46%-20.27%-15.88%-2.97%-3.19%
FCF Yield
-2.01%-4.00%-17.75%-12.67%0.68%-2.57%
Buyback Yield / Dilution
-12.21%-27.98%-19.35%-19.78%-231.12%-162.72%
Updated Nov 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q